Alexion Not Scared Of Amgen Biosimilar Threat To Soliris
Companies Settled Eculizumab Litigation In US Earlier This Year
Alexion Pharmaceuticals is confident of its strategy to switch patients from Soliris to Ultomiris as the threat of biosimilar competition to the former looms. But launching a biosimilar to Soliris alone will be a challenge, the company maintains.
